July 17, 2001

Tanabe Press Release

TANABE SEIYAKU Granted Rights for Bepotastine Besilate

For Ophtalmic Use to SENJU SEIYAKU (JAPAN)

Tanabe Seiyaku Co., Ltd. (Mr. Toshio Tanaka, President and CEO) announced today that Tanabe Seiyaku

has granted a right to Senju Seiyaku Co., Ltd. (Mr. Shoji Yoshida, President) for bepotastine besilate which

is an active ingredient of the anti-allergic product, TALION of Tanabe Seiyaku. Senju receives an

exclusive worldwide right, except for some Asian countries, to develop, manufacture and market for

ophthalmic use.

Bopotasitine besilate has been originally synthesized and identified by Ube Industries, Ltd. (Mr.

Kazumasa Tsunemi, President). Ube Industries and Tanabe Seiyaku has jointly developed and launched as

TALION tablets for treatment of allergic rhinitis last October in Japan. Since bepotastine besilate has a

strong histamine antagonistic action as well as an inhibitory action of migration of eosinophils (a kind of

leucocytes) to inflamed tissues, it is expected to be effective against main symptoms such as itching in

seasonal allergic conjunctivitis caused by pollens as well as perennial allergic conjunctivitis caused by

house dusts etc. Furthermore, bepotastine besilate is rich in water solubility, and suitable for applying

eye-drop products.

As a pioneer in the ophthalmic area, Senju is eager to develop innovative products and has excellent

expertise and experiences as a specialized company in this area.

Tanabe Seiyaku has already licensed out ecabet sodium (an agent for treatment of gastritis and gastric

ulcer as GASTROM in Japan) for treatment of dry eyes to Senju. Ecabet sodium is currently under

development by Senju. Therefore, this new license for bepotastine besilate is the second collaboration

between both companies.

For further information, please contact:

Corporate Communications Division.

Osaka

Tel: +81-6-6205-5211 Fax: +81-6-6205-5105

Tokyo

Tel: +81-3-3230-6757 Fax: +81-3-3230-6888

